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Objectives: Among adults started on antiretroviral treatment (ART) in a rural district
hospital (a) to determine the cumulative proportion of deaths that occur within 3 and
6monthsofstartingART,and(b)toidentifyriskfactorsthatmaybe associatedwithsuch
mortality.
Design and setting: A cross-sectional analytical study set in Thyolo district, Malawi.
Methods: Over a 2-year period (April 2003 to April 2005) mortality within the ﬁrst
3 and 6 months of starting ART was determined and risk factors were examined.
Results: A total of 1507 individuals (517 men and 990 women), whose median age was
35 years were included in the study. There were a total of 190 (12.6%) deaths on ART of
which116(61%)occurredwithintheﬁrst3months(veryearlymortality)and150(79%)
during the ﬁrst 6 months of initiating ART. Signiﬁcant risk factors associated with such
mortality included WHO stage IV disease, a baseline CD4 cell count under 50cells/ml
and increasing grades of malnutrition. A linear trend in mortality was observed with
increasing grades of malnutrition (x
2 for trend¼96.1, P 0.001) and decreasing CD4
cell counts (x
2 for trend¼72.4, P 0.001). Individuals who were severely malnour-
ished [body mass index (BMI)<16.0kg/m
2] had a six times higher risk of dying in the
ﬁrst 3 months than those with a normal nutritional status.
Conclusions: Among individuals starting ART, the BMI and clinical staging could be
importantscreeningtoolsforusetoidentifyandtargetindividualswho,despiteART,are
still at a high risk of early death.  2006 Lippincott Williams & Wilkins
AIDS 2006, 20:2355–2360
Keywords: malawi, HIV/AIDS, antiretroviral therapy, malnutrition, early
mortality
Introduction
Malawi is a small, resource-poor country in sub-Saharan
Africa with one of the highest HIV/AIDS prevalence
rates in the world with 14% of those aged 15–49 infected
[1]. In 2003, the National AIDS Commission estimated
that there were 900000 people living with HIV/AIDS
with 86000 adult and childhood deaths attributed to
HIV/AIDS annually, and an estimated 170000 people in
need of antiretroviral treatment (ART) [1].
ART is known to dramatically improve survival of
patients living with HIV/AIDS [2,3]. Since early 2004,
Malawi has embarked on an ambitious plan to scale-up
ART country-wide and by the end of December 2005, a
total of 37840 patients had been started on ART [4,5].
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Early outcomes of patients initiated on ART in Malawi
and other developing countries show that despite ART,
between 10 and 15% of individuals die within a median
follow-up period of about 15 months [4,6,7]. A sub-
stantial proportion(about 70%)ofthese deaths occur very
early (within the ﬁrst 3 months) after starting ART.
Identifying individualswhoareatriskof suchearly deaths
would be useful for targeting potential interventions
to prevent such deaths. Factors associated with early
mortality in patients placed on ART in resource-limited
settings are at present not well characterized.
We conducted a study among adults started on ART in a
rural district of Malawi in order to: (a) determine the
cumulative proportion of deaths that occur within 3 and
6monthsofstartingART;and(b)identifyriskfactorsthat
may be associated with such deaths.
Methods
Study setting and population
This study was conducted between April 2003 and June
2005 in Thyolo district, a rural district in southern
Malawi with approximately 500000 inhabitants. All
adults who were ART naive and starting treatment in the
main district hospital (Thyolo hospital) HIV/AIDS clinic
over a 2-year period (April 2003 to April 2005) were
included in the study.
Counseling and rapid on-site HIV-testing (CT) is
available in the hospital and 10 other public health
facilities in the district. HIV testing is conducted using
rapid whole blood test kits and follows the World Health
Organization (WHO)strategyII forHIVantibodytesting
[8]. All HIV-positive individualswho present at the HIV/
AIDS clinic undergo a complete medical assessment for
HIV-related diseases and they are subsequently cate-
gorized using the WHO clinical staging system [9].
Individuals are managed for their opportunistic diseases
and those in WHO stage III and IV are offered
cotrimoxazole prophylaxis at the dose of 960mg daily,
provided there are no contraindications. A community
network of home-based care volunteers and nurses
facilitate referrals of known HIV-positive individuals and
others with suspected HIV-related diseases to the hospital
HIV/AIDS clinic [10].
Antiretroviral therapy eligibility, regimens and
treatment outcomes
All individuals classiﬁed in WHO stage II with a CD4
count 200cells/ml, in WHO stage III with CD4 cell
count  350cells/ml or in WHO stage IV irrespective of
CD4 cell count are considered eligible for ART. In most
facilities in Malawi individuals in WHO stage III are
considered eligible for ARTon clinical grounds alone as
there is no access to CD4-lymphocyte counts. Although
not a requirement in the rest of the country, in Thyolo,
ART-eligible individuals are required to return with a
patient guardian (or next of kin) to prepare for ART
initiation, to try to ensure treatment support. Patients
and guardians undergo group and individual counseling
sessions and are educated on HIV infection, and the
implications of ART. The process of preparation for ART
initiation takes between 4 and 8 weeks. The ﬁrst-line
ARTregimen in Malawi [9,11] is a ﬁxed dose combina-
tion of stavudine (d4T), lamivudine (3TC) and nevira-
pine (NVP) (Triomune; CIPLA, Bombay, India). In cases
of d4T and NVP-related side-effects, the respective
alternatives are zidovudine (ZDV) and efavirenz (EFV).
Second-line regimens are available in cases of ﬁrst-line
failure [11].
Treatmentoutcomesaremonitoredeverymonthusingthe
patient master card, and every quarter by cohort analysis,
which is carried out retrospectively every 3 months using
patient master cards and an ART patient register, as has
been described previously [12]. Outcomes are standar-
dized and include; alive and on ART, died, lost to follow-
up, stopped and transferred out. ART is offered free of
chargein Thyolo andall public healthfacilities inMalawi.
Data collection and statistical analysis
A structured record form and patient cards were used to
gather information on basic demographic data, WHO
clinical stage, CD4 cell counts, and opportunistic infec-
tions including tuberculosis (TB). CD4 cell counts were
systematically performed in all patients, using strict
quality control standards [13].
On admission, height and weight measurements were
carried out and this was used to determine the body mass
index[BMI;weight(kg)dividedbyheight(m)
2].Anormal
BMI was deﬁned as 18.5–24.9kg/m
2. Malnutrition
was deﬁned as a BMI<18.5kg/m
2. Different degrees
of malnutrition were deﬁned as follows: mild malnutri-
tion, BMI¼17.0 to 18.4kg/m
2; moderate malnutrition,
BMI¼16.0 to 16.9kg/m
2; and severe malnutrition,
BMI<16.0kg/m
2. The personnel conducting weight
and height measurements had been trained and were
supervised during the entire course of the study.
The cumulative proportion ofdeathsthat occurred within
theﬁrst3months(veryearlymortality)and6months(early
mortality) of initiating ARTwere designated as dependent
variables for identifying potential risk associations. Since
Thyolo has a well developed network of community
volunteers and nurses that follow up HIV-positive indi-
vidualsathome,reliableascertainmentofdeathsispossible
[10]. The measuresofriskwere determinedby crude odds
ratios (ORs) and adjusted odds ratios (adjusted ORs). The
ORs were adjusted using multi-variate logistic regression,
andallrelatedP-valueswerebasedontheWaldtest.Thex
2
test for trend was used to test for linear trends. Survival
estimates between groups were determined using the
2356 AIDS 2006, Vol 20 No 18Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Kaplan–Maier method and compared using the Cox–
Mantel (log-rank test). The level of signiﬁcance was set at
P¼0.05 or less and 95% conﬁdence intervals (CI) were
used throughout. Data was analysed using the STATA 8.2
software(StataCorporation,CollegeStation,Texas,USA).
Results
Characteristics of the study population
Therewere1584 adultswhowere started on ART during
the study period. Of these, BMI was not recorded in
77 patients who were excluded from the study. Among
the 1507 individuals in whom data was complete, there
were 517 (34%) men and 990 women, whose median
agewas35years[interquartilerange(IQR),30–42years].
At ART initiation, 1149 (76%) adults were in WHO
stage III, 338 (23%) were in WHO stage IV, and 20
(1%) were in WHO stage II but with a CD4 cell
count 200cells/ml. A total of 225 (15%) had active TB
and were also receiving anti-TB treatment. There were
542 (36%) adults starting ARTwho were malnourished.
Of these, 250 (17%) had mild malnutrition, 127 (8%)
had moderate malnutrition and 165 (12%) were severely
malnourished. The median CD4 cell count for all indi-
viduals at ART initiation was 123cells/ml (IQR, 58–
206cells/ml) and the mean BMI was 19.6kg/m
2.
Patientswerefollowedupforatotalof1361person-years.
Speciﬁc ART regimens included d4T/3TC/NVP in
1412 (93.7%) patients, d4T/3TC/EFV in 66 (4.4%)
patients, ZDV/3TC/NVP in 20 (1.3%) patients, and
ZDV/3TC/EFV in ﬁve (0.3%) patients. Five (0.3%)
patients were on a second line regimen of ZDV/
didanosine/nelﬁnavir.
Treatment outcomes at the end of April 2005 included:
1181 (78%) alive and on ART, 38 (2.5%) transferred out,
46 (3%) lost to follow-up and 52 (3.5%) stopped ART.
There were 190 (12.6%) deaths after starting ART. All
individuals in the study were receiving cotrimoxazole
prophylaxis, which had been initiated either before or
at the same time as ART. Adverse side effects to ART
were reported in 56 (3.7%) patients, including 48 cases of
peripheral neuropathy, ﬁve cases of skin reactions, and
three cases of hepatotoxicity. Two patients, one of whom
had peripheral neuropathy and another who had skin
reactions decided to stop ART permanently because of
side effects.
Early deaths, risk factors associated with such
deaths and differences in survival between
groups
Out of 190 ascertained deaths, 116 (61%) occurred in the
ﬁrst 3 months and 150 (79%) in the ﬁrst 6 months.
Figure 1 shows the cumulative incidence of deaths in
patients started on ART.
Signiﬁcant risk factors associated with mortality in the
ﬁrst 3 months included WHO stage IV disease, a CD4
cell count under 50cells/ml and increasing grades of
malnutrition (Table 1). These were similar for mortality
Very early deaths in patients placed on ART Zacharia et al. 2357
Fig. 1. Cumulative incidence of death since starting antire-
troviral treatment (ART).
Table 1. Risk factors associated with very early deaths (during ﬁrst




deaths (%) OR Adjusted OR
a P
Gender
Female 80/990 (8.1) 1 1
Male 52/517 (10.1) 1.3 1.2 (0.8–1.8) 0.40
Age (years)
 35 49/681 (7.2) 1 1
>35 67/826 (8.1) 1.2 1.0 (0.6–1.4) 0.81
WHO Stage
Stage II 2/20 (10) 1.8 2.9 (0.6–13.4) 0.17
Stage III 68/1149 (5.9) 1 1 –
Stage IV 46/338 (13.6) 2.5 2.1 (1.4–3.3) 0.001
CD4 cell count (cells/ml)
b
200–350 19/406 (4.7) 1 1
51–200 48/790 (6.1) 1.3 1.2 (0.7–2.1) 0.44
 50 49/311 (15.8) 3.8 2.2 (1.2–4.0) 0.01
Active tuberculosis
c
Present 15/225 (6.7) 1 1
Absent 101/1282 (7.9) 1.1 1.4 (0.8–2.6) 0.25
BMI on starting ART (kg/m
2)
d
 18.5 37/962 (3.9) 1 1
17.0–18.4 20/250 (8.0) 2.1 2.1 (1.2–3.8) 0.01
16.0–16.9 15/127 (11.8) 3.3 2.4 (1.7–6.3) <0.001
 15.9 44/168 (26.2) 7.6 6.0 (4.6–12.7) <0.001
BMI, body mass index; OR, odds ratio; WHO, World Health
Organization.
aAdjusted for gender, age, World Health Organisation clinical stage,
CD4 count, presence or absence of active tuberculosis, and body
mass index on starting antiretroviral treatment; 95% conﬁdence
intervals in parenthesis.
bx
2 for trend¼72.4; P¼<0.001.
cPulmonary (smear positive or negative) and extra-pulmonary tuber-
culosis.
dBMI; x
2 for trend¼96.1; P¼<0.001.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
within the ﬁrst 6 months (Table not shown). The results
for mortality within the ﬁrst 6 months included: WHO
stage IV, OR, 2.1 (95% CI, 1.4–3.0; P<0.001); CD4
cell count 50cells/ml, OR, 2.2 (95% CI, 1.3–3.7;
P<0.01); BMI¼17.0–18.4kg/m
2, OR, 1.8 (95% CI,
1.1–3.0; P¼0.02); BMI¼16.0–16.9kg/m
2, OR, 2.4
(95% CI, 1.3–4.3; P<0.01); and BMI 15.9kg/m
2,
OR, 5.8 (95% CI, 3.7–9.1; P<0.001).
Mortality within the ﬁrst 3 months was 3.9% in patients
with normal nutrition, 8.0% in those with mild malnutri-
tion, 11.8% in those with moderate malnutrition, and
26.2% in those with severe malnutrition (x
2 for trend¼
96.1; P 0.001, Table 1). Similarly, a linear trend in death
rates was observed with decreasing baseline CD4 cell
counts on starting ART (x
2 for trend¼72.4; P<0.001).
For mortality within the ﬁrst 6 months, this trend was
maintained both for increasing grades of malnutrition
(x
2 for trend¼84.03; P<0.001) and decreasing baseline
CD4cellcounts(x
2fortrend¼23.5;P<0.001).Figures2
and 3 depict signiﬁcant differences in survival probability
withdifferinggradesofBMIandbaselineCD4 cellcounts
on starting ART.
In 105 (91%) of 116 individuals who died in the ﬁrst
3months,anactiveWHOdeﬁningopportunisticdisease
was recorded and this was attributed as the main cause
of death. Attributed causes of death included: 26 (22%)
oral recurrent Candida, 15 (13%) oesophageal candi-
diasis, 13 (11%) Kaposi’s sarcoma, 12 (10%) severe
bacterialpneumonia,10(9%)activetuberculosis,10(9%)
chronic diarrhea>1 month, seven (6%) cryptococcal
meningitis, six (5%) chronic wasting, four (3%) chronic
fever, and two (2%) Pneumocystis jeroveci pneumonia. No
speciﬁc cause of death was recorded in 11 (10%)
individuals. Seventy-nine (68%) of 116 patients who




This study shows in patients started on ART in a rural
setting, the great majority of deaths (six out of every ten)
occur within 3 months of starting treatment. Signiﬁcant
risk factors associated with such ‘very early deaths’
included increasing grades of malnutrition, WHO stage
IV disease and a CD4 cell count under 50cells/ml.
Although, it may be argued that the overall death rate of
12.6%isacceptable,wefeelthataddressingearlymortality
is important in order to improve overall program
outcomes and particularly the credibility of the ART
program in the eyes of patients, health workers and the
community at large.
The strengths of this study are that a large number of
patientswerestudied,deathswerereliablyascertained,the
loss to follow-up was low and as the data comes from a
program setting, the ﬁndings probably reﬂect operational
reality on the ground. One of the limitations of this study
was that the exact cause(s) of death could not be deter-
mined, as there were no post-mortem facilities nor access
to sophisticated laboratory diagnostic facilities, and there-
fore the attributed cause(s) of death in this study might be
erroneous. An additional limitation is the lack of viral
loads to assess response to therapy.
There are several possible reasons for very early mortality
in patients started on ART. For example; late diagnosis of
HIV, delays in the ART initiation process at the health
facility,delayedpresentationofpatientsandthusadvanced
HIV/AIDS disease, and life-threatening HIV-related
complications such as severe anemia, or bacteremia
[14,15]. Drug-induced adverse reactions or immune
reconstitution disease (IRIS) are other possible causes of
death.However,theincidenceof adversereactionstoﬁrst
line ART in this setting is low [16] and patients are well
educated to immediately stop ART in case of such an
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Fig. 2. Survival probability among patients with different
gradesofmalnutritionwhen startingantiretroviral treatment
(ART). BMI, body mass index.
Fig. 3. Survival probability among patients with baseline
CD4 cell counts < – 50 or >50cells/ml on starting antiretro-
viral treatment (ART).Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
event. Unfortunately, due to the absence of a universal
case deﬁnition for IRIS that is applicable to our setting,
we were unable to assess the relative contribution of IRIS
particularly with TB [17].
We have shown that increasing grades of malnutrition are
strongly associated with very early mortality. However,
we do not know if nutritional impairment on its own
predisposes to early death, or whether it is a marker of
extensive HIV disease or other covert opportunistic
infections. For example, 40% of patients dying with the
HIV wasting syndrome in Cote d’Ivoire were found at
autopsy to have disseminated TB [18].
Preventing early deaths in patients started on ARTwill be
a major challenge in resource-poor settings such as
Malawi that are rapidly trying to scale-up ART. There are
several possible ‘ways forward’.
Early diagnosis of HIV-status and early access to preven-
tive medication such as cotrimoxazole prophylaxis could
have a beneﬁcial effect on the incidence of certain
opportunistic infections, the evolution of CD4 cell
counts and viral load [19] and HIV related mortality [20].
Patients already on cotrimoxazole prophylaxis (when
starting ART) might be in a better physical state and thus
at a lower risk of very early mortality.
Minimizing delays in ART initiation and the burden of
scheduled visits to the hospital for ART initiation is
needed, and this could be achieved by basing ART
eligibility on simple clinical criteria (WHO staging)
without CD4 cell counting, not insisting on always
having a guardian present, and decentralizing group
counseling sessions to the community under the aegis of
community nurses and ART support groups. This last
strategy would serve to enhance community empower-
ment in ART delivery. Finally, individuals in WHO stage
IV disease, should be ‘fast-tracked’ for ART initiation.
At present, the initiation of ART is ‘centralized’ to the
main district hospital facility. In a rural setting, where
inhabitants are mainly subsistence farmers earning less
than US$4 per week [21], this is likely to be an ‘access
barrier’ contributing to delayed presentation for ART
[22]. ‘Decentralization’ of ART and follow-up to health
centres closer to home communities would be an impor-
tant step to addressing this bottleneck, although limited
infrastructure and shortage of human resources make this
a considerable challenge [23].
Almost all patients who died within the ﬁrst 3 months
of starting ART had WHO stage IV diseases, afﬁrming
their advanced stage of immune suppression. Although
Thyolo hospital is fortunate to have access to exceptional
resources in terms of clinical staff and drug supplies
through the international non-governmental organiza-
tion (Medecins Sans Frontieres), these patients still died.
There might be a number of possible ways forward in
addressing this speciﬁc problem. First, there is a need
to prevent patients presenting ‘too late’, possibly by
increasing community awareness, improving HIV/AIDS
health-seeking behavior and addressing access issues.
Second, patients who are malnourished should be offered
intensivenutritionalrehabilitationandnutritionalsupple-
ments. Third, TB in the late stages of immunodeﬁciency
and bacteremia in patients who are malnourished may
present inan atypical or‘covert’ mannerand the diagnosis
may be missed [18]. Until better diagnostic techniques
become available, a more systematic search for TB in
patients with low BMI including detailed questioning
about cough, sputum examination for anyone who
coughs (even if less than 3 weeks), a chest X-ray and
abdominal ultrasound for glands might be cost-effective
approaches, meriting operational research. Diagnosis of
bacteremia in most African hospitals is difﬁcult because of
the lack of blood culture facilities. Patients at risk of very
early mortality might therefore require an empirical
course of antibiotics or antibiotic prophylaxis with drugs
such as ciproﬂoxacin to treat, or prevent commonly
occurring but potentially lethal infections due to Strep-
tococcus pneumoniae and non-typhoidal Salmonella [14,15].
The results of this study might help in ﬁnding immediate
solutions to this problem. Assessing the BMI and examin-
ing patients for active WHO deﬁning diseases constitute
part of routine clinical procedures in the Thyolo clinic, as
in other HIV/AIDS clinics in Malawi and thus do not
add any additional workload for clinic staff. This is an
important operational consideration for settings which
are often overloaded and understaffed [23]. HIV-positive
individuals with a BMI under 18.5 have a ‘two to six
times’ higher risk of dying within the ﬁrst 3 months of
starting ART than those with a normal nutritional status.
Individuals in WHO stage IV have about twice the risk
of dying than those in WHO stage III. Although it is
currently unclear whether interventions (nutritional
rehabilitation and antibiotic treatment) might reduce
early mortality in these sub-groups, they could never-
theless be explored while awaiting the results of
randomized controlled trials. In a rural district of Malawi,
theBMIandclinicalstagingcouldbeimportantscreening
toolstoidentifyindividualswho,despiteART,arestillata
high risk of very early death.
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